Amarin Co. plc Sees Significant Growth in Short Interest (AMRN)

Share on StockTwits

Amarin Co. plc (NASDAQ:AMRN) was the recipient of a significant increase in short interest in the month of May. As of May 30th, there was short interest totalling 28,752,172 shares, an increase of 8.1% from the May 15th total of 26,592,026 shares, AnalystRatings.Net reports. Approximately 17.4% of the company’s shares are short sold. Based on an average daily volume of 1,497,932 shares, the days-to-cover ratio is currently 19.2 days.

AMRN has been the subject of a number of recent research reports. Analysts at MKM Partners reiterated a “fair value” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. They now have a $1.50 price target on the stock, down previously from $2.00. Separately, analysts at Aegis reiterated a “hold” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. Finally, analysts at Citigroup Inc. downgraded shares of Amarin Co. plc from a “buy” rating to a “neutral” rating in a research note on Friday, May 9th. Eleven analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $4.18.

Amarin Co. plc (NASDAQ:AMRN) opened at 1.53 on Friday. Amarin Co. plc has a 1-year low of $1.28 and a 1-year high of $7.40. The stock’s 50-day moving average is $1.49 and its 200-day moving average is $1.73. The company’s market cap is $264.5 million.

Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Friday, May 9th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.65 million. The company’s quarterly revenue was up 378.3% on a year-over-year basis. On average, analysts predict that Amarin Co. plc will post $-0.55 earnings per share for the current fiscal year.

Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Teens Arrested in Shooting Plot
Teens Arrested in Shooting Plot
Volvo Cars Selling Fast
Volvo Cars Selling Fast
Girl Falls over 550 Feet at Yellowstone National Park
Girl Falls over 550 Feet at Yellowstone National Park
Julian Assange Says He Will Leave Embassy a Free Man
Julian Assange Says He Will Leave Embassy a Free Man
Google Acquires Jetpac for Social Travel Apps
Google Acquires Jetpac for Social Travel Apps
Microsoft Windows Mobile Phone Still Struggling
Microsoft Windows Mobile Phone Still Struggling


 
© 2006-2014 WKRB News.